JP5847730B2 - ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節 - Google Patents

ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節 Download PDF

Info

Publication number
JP5847730B2
JP5847730B2 JP2012547323A JP2012547323A JP5847730B2 JP 5847730 B2 JP5847730 B2 JP 5847730B2 JP 2012547323 A JP2012547323 A JP 2012547323A JP 2012547323 A JP2012547323 A JP 2012547323A JP 5847730 B2 JP5847730 B2 JP 5847730B2
Authority
JP
Japan
Prior art keywords
testosterone
formulation
therapeutic agent
phytosterol
concentrated emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012547323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013516433A (ja
JP2013516433A5 (enExample
Inventor
ディングラ，オム
Original Assignee
ディッフェレンシャル ドラッグ ディベロップメント アソシエイツ，エルエルシー
ディッフェレンシャル ドラッグ ディベロップメント アソシエイツ，エルエルシー
エスオーブイ セラピューティクス
エスオーブイ セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディッフェレンシャル ドラッグ ディベロップメント アソシエイツ，エルエルシー, ディッフェレンシャル ドラッグ ディベロップメント アソシエイツ，エルエルシー, エスオーブイ セラピューティクス, エスオーブイ セラピューティクス filed Critical ディッフェレンシャル ドラッグ ディベロップメント アソシエイツ，エルエルシー
Publication of JP2013516433A publication Critical patent/JP2013516433A/ja
Publication of JP2013516433A5 publication Critical patent/JP2013516433A5/ja
Application granted granted Critical
Publication of JP5847730B2 publication Critical patent/JP5847730B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012547323A 2009-12-31 2010-12-31 ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節 Active JP5847730B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29176909P 2009-12-31 2009-12-31
US61/291,769 2009-12-31
PCT/US2010/062649 WO2011082384A2 (en) 2009-12-31 2010-12-31 Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013124891A Division JP5836322B2 (ja) 2009-12-31 2013-06-13 ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節

Publications (3)

Publication Number Publication Date
JP2013516433A JP2013516433A (ja) 2013-05-13
JP2013516433A5 JP2013516433A5 (enExample) 2015-05-07
JP5847730B2 true JP5847730B2 (ja) 2016-01-27

Family

ID=44188274

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012547323A Active JP5847730B2 (ja) 2009-12-31 2010-12-31 ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節
JP2013124891A Active JP5836322B2 (ja) 2009-12-31 2013-06-13 ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013124891A Active JP5836322B2 (ja) 2009-12-31 2013-06-13 ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節

Country Status (8)

Country Link
US (5) US20110160168A1 (enExample)
EP (2) EP2682111A1 (enExample)
JP (2) JP5847730B2 (enExample)
CA (1) CA2822435C (enExample)
ES (1) ES2710149T3 (enExample)
PL (1) PL2519230T3 (enExample)
PT (1) PT2519230T (enExample)
WO (1) WO2011082384A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
AU2006236564B2 (en) 2005-04-15 2011-02-17 Besins Healthcare Luxembourg S.A.R.L. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
CA2822435C (en) 2009-12-31 2018-09-11 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
MX340951B (es) 2011-09-29 2016-07-29 Plx Pharma Inc Portadores dependientes del ph para la liberacion dirigida de productos farmaceuticos a lo largo del tracto gastrointestinal, composiciones de los mismos, y fabricación y uso de las mismas.
EP2934591B1 (en) * 2012-12-20 2017-08-09 Solural Pharma Aps Solid oral dosage form of testosterone derivative
ES2907284T3 (es) 2013-03-15 2022-04-22 Marius Pharmaceuticals Llc Formulaciones de emulsión
US10201549B2 (en) * 2013-06-14 2019-02-12 Professional Compounding Centers Of America (Pcca) Testosterone combined with anastrozole injection solutions
US9603811B2 (en) * 2013-12-11 2017-03-28 Health-Ever Biotech Co., Ltd Pharmaceutical compositions of carotenoid chylomicrons
EP3157505B1 (en) * 2014-06-17 2019-07-24 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
PL3157508T3 (pl) * 2014-06-19 2021-05-17 Solural Pharma ApS Związki lipofilowe w postaci stałej dawkowane doustnie
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
RU2017111503A (ru) * 2014-08-29 2018-10-05 Липосин Инк. КОМПОЗИЦИИ(17-β)-3-ОКСОАНДРОСТ-4-ЕН-17-ИЛ УНДЕКАНОАТА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
KR101679380B1 (ko) * 2015-09-10 2016-11-25 주식회사 유유제약 두타스테리드를 포함하는 약학적 조성물 및 이를 포함하는 캡슐 제형
KR101634382B1 (ko) * 2015-10-20 2016-06-28 미래제약 주식회사 타다라필 경구용 액제
JP6840423B2 (ja) * 2016-02-29 2021-03-10 有限会社 Ｉｐｅ 米糠酵素処理物の利用法
EP3528804B1 (en) * 2016-10-20 2023-07-26 APIRX Pharmaceutical USA, LLC Chewing gum composition comprising cannabinoids and opioid agonists and/or antagonists
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
EP3628005A4 (en) * 2017-08-14 2021-01-20 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
CN109419771B (zh) * 2017-08-28 2022-02-01 中国人民解放军军事医学科学院毒物药物研究所 十一酸睾酮缓释药物组合物、其制备方法及用途
WO2019046582A1 (en) 2017-08-30 2019-03-07 Antares Pharma, Inc. TESTOSTERONE ESTER TRIGLYCERIDE FORMULATIONS
CN107875034B (zh) * 2017-10-11 2021-01-26 广东药科大学 一种复合抗氧化自微乳及其制备方法和应用
JP6887520B2 (ja) * 2017-11-01 2021-06-16 富士フイルム株式会社 経口医薬組成物
US20210023029A1 (en) * 2017-11-06 2021-01-28 Catabasis Pharmaceuticals, Inc. Edasalonexent dosing regimen for treating muscular dystrophy
US20200323773A1 (en) * 2017-11-07 2020-10-15 Poviva Corp. Food and beverage compositions comprising pde5 inhibitors
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
JP2021531348A (ja) 2018-07-20 2021-11-18 リポシン，インク． 肝臓病
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
JP2022523704A (ja) * 2019-01-25 2022-04-26 シェンチェン・ファーマシン・カンパニー・リミテッド 医薬組成物
US12403146B2 (en) 2019-10-30 2025-09-02 Marius Pharmaceuticals, Inc. Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment
EP4125820A4 (en) * 2020-03-26 2024-04-10 PLx Opco Inc. Pharmaceutical carriers capable of ph dependent reconstitution and methods for making and using same
BR112023024162A2 (pt) * 2021-05-19 2024-02-06 Marius Pharmaceuticals Llc Terapia oral preferida com undecanoato de testosterona para obter o tratamento de substituição de testosterona

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147783A (en) * 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
DE3774832D1 (de) 1986-09-25 1992-01-09 Nec Corp Einrichtung zur ermittlung der bit-phasendifferenz.
US5229370A (en) * 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US6696484B2 (en) * 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
CA2313024C (en) * 1997-12-10 2008-06-03 Severson, Mary L. Pharmaceutical compositions containing an omega-3 fatty acid oil
DE69939258D1 (de) 1998-05-15 2008-09-18 Nasa Johnson Space Ct Mikrokapseln mit extern ausgelöster öffnung
US6087353A (en) * 1998-05-15 2000-07-11 Forbes Medi-Tech Inc. Phytosterol compositions and use thereof in foods, beverages, pharmaceuticals, nutraceuticals and the like
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US6977083B1 (en) * 1998-10-02 2005-12-20 Jenapharm Gmbh & Co. Kg Bioadhesive tablet containing testosterone/testosterone ester mixtures and method for producing a predetermined testosterone time-release profile with same
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
MXPA03001147A (es) * 2000-08-23 2003-10-06 Akzo Nobel Nv Nueva formulacion de ester de testosterona para uso humano.
US6838484B2 (en) * 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US6743448B2 (en) * 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
US20030203043A1 (en) * 2002-04-25 2003-10-30 A. Braswell Composition and method for increasing testosterone levels
US20030212046A1 (en) * 2002-05-07 2003-11-13 Kapac, Llc Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
US20050287203A1 (en) * 2002-05-08 2005-12-29 Nijs De H Formulation comprising testosteron undecanoate and castor oil
US6742488B2 (en) 2002-07-18 2004-06-01 Kohler Co. Component for governing air flow in and around cylinder head port
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20040087564A1 (en) * 2002-10-31 2004-05-06 Wright D. Craig Delivery composition and method
US20080305177A1 (en) * 2002-11-14 2008-12-11 Alvin Kershman Method of administering testosterone
JP2006508967A (ja) * 2002-11-14 2006-03-16 シャー／カーシュマン ラボラトリーズ インコーポレイテッド 改善された持続放出性を有する経口テストステロン供与システム
US6742448B1 (en) 2002-12-09 2004-06-01 J. U. Manufacturing Co., Inc. Baler with doors and platen positions interlocks
US20040115226A1 (en) * 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
US20200069805A1 (en) 2003-11-03 2020-03-05 Lipocine Inc. Pharmaceutical compositions with synchronized solubilizer release
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
JP2007512334A (ja) * 2003-11-20 2007-05-17 ゾマネックス，エルエルシー ジヒドロテストステロンの上昇に関連した病状を治療するための方法および製剤
WO2005053660A2 (en) * 2003-12-03 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising danazol
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
US7138389B2 (en) * 2004-02-09 2006-11-21 University Of Washington Oral androgen therapy using modulators of testosterone bioavailability
RU2394576C2 (ru) * 2004-08-10 2010-07-20 Энзимотек Лтд. Способы лечения, требующие фитокомпонентов
WO2006084312A1 (en) * 2005-02-09 2006-08-17 Acrux Dds Pty Ltd Method of promoting hair growth
US20070154533A1 (en) * 2005-04-13 2007-07-05 Dudley Robert E Method of increasing testosterone and related steriod concentrations in women
AU2006236564B2 (en) 2005-04-15 2011-02-17 Besins Healthcare Luxembourg S.A.R.L. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) * 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US20080200533A1 (en) * 2005-07-04 2008-08-21 Ramu Krishnan Drug or Pharmaceutical Compounds and a Preparation Thereof
US7588274B2 (en) 2005-07-06 2009-09-15 Landon Worthington Building block lifting and carrying tool
EP2010291A2 (en) * 2006-03-31 2009-01-07 Panacea Biotec Ltd. Novel compositions for hair disorders and process of preparation thereof
US20070254026A1 (en) * 2006-05-01 2007-11-01 Forbes Medi-Tech Inc. Softgel capsules
US20080124387A1 (en) * 2006-11-27 2008-05-29 Kapac, Llc Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients
US20080261937A1 (en) * 2007-03-23 2008-10-23 Dudley Robert E Pharmaceutical compositions and method for treating pediatric hypogonadism
US20090077961A1 (en) 2007-09-24 2009-03-26 Baker David M Heat Concentrator Piston and Chamber
EP2140861A1 (en) 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2229936B1 (en) 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
US20110263552A1 (en) 2009-12-31 2011-10-27 Sov Therapeutics Modulation of side effect profile of 5-alpha reductase inhibitor therapy
US20130303495A1 (en) 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
CA2822435C (en) 2009-12-31 2018-09-11 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
MX352328B (es) 2010-04-12 2017-11-21 Clarus Therapeutics Inc Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
US8512794B2 (en) * 2010-05-20 2013-08-20 Perlman Consulting, Llc Oleate ester phytosterol compositions
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US9375437B2 (en) * 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120135074A1 (en) * 2010-11-30 2012-05-31 Chandrashekar Giliyar High-Strength Testosterone Undecanoate Compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EP2934591B1 (en) 2012-12-20 2017-08-09 Solural Pharma Aps Solid oral dosage form of testosterone derivative
ES2907284T3 (es) 2013-03-15 2022-04-22 Marius Pharmaceuticals Llc Formulaciones de emulsión
EP3157505B1 (en) 2014-06-17 2019-07-24 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
US20160184321A1 (en) 2014-09-24 2016-06-30 Lipocine Inc. Compositions and their use in oral dosing regimens
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20170319596A1 (en) 2015-11-10 2017-11-09 Lipocine Inc. Methods for improving quality of life or sexual domain function and composition useful in the methods
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
JP2021531348A (ja) 2018-07-20 2021-11-18 リポシン，インク． 肝臓病
EP3856142A1 (en) 2018-09-25 2021-08-04 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US20200197413A1 (en) 2018-12-20 2020-06-25 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
US12403146B2 (en) 2019-10-30 2025-09-02 Marius Pharmaceuticals, Inc. Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment
CN115955959A (zh) 2020-02-26 2023-04-11 康普萨姆公司 纳米结构脂质载体递送系统、组合物和方法
US11464735B2 (en) 2020-09-25 2022-10-11 Lipocine Inc. Fixed dose oral testosterone undecanoate compositions and use thereof
BR112023024162A2 (pt) 2021-05-19 2024-02-06 Marius Pharmaceuticals Llc Terapia oral preferida com undecanoato de testosterona para obter o tratamento de substituição de testosterona

Also Published As

Publication number Publication date
CA2822435A1 (en) 2011-07-07
CA2822435C (en) 2018-09-11
PT2519230T (pt) 2019-01-18
US10576090B2 (en) 2020-03-03
WO2011082384A2 (en) 2011-07-07
US12295961B2 (en) 2025-05-13
EP2519230A2 (en) 2012-11-07
US20140011780A1 (en) 2014-01-09
JP2013516433A (ja) 2013-05-13
JP2013177454A (ja) 2013-09-09
US20180243319A1 (en) 2018-08-30
JP5836322B2 (ja) 2015-12-24
ES2710149T3 (es) 2019-04-23
US10576089B2 (en) 2020-03-03
WO2011082384A3 (en) 2011-11-10
US11590146B2 (en) 2023-02-28
US20110160168A1 (en) 2011-06-30
US20200390784A1 (en) 2020-12-17
EP2519230A4 (en) 2013-07-10
EP2682111A1 (en) 2014-01-08
PL2519230T3 (pl) 2019-05-31
EP2519230B1 (en) 2018-10-10
US20240000798A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
US12295961B2 (en) Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US12357643B2 (en) Emulsion formulations
US20110263552A1 (en) Modulation of side effect profile of 5-alpha reductase inhibitor therapy
US20130303495A1 (en) Emulsion formulations
US20200316093A1 (en) Abiraterone acetate lipid formulations
JP5727925B2 (ja) 脂質組成物
JP2022517217A (ja) 経口薄フィルム
AU2016324349A1 (en) Ubiquinone and ubiquinol compositions, and methods relating thereto
HK1193359A (en) Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
HK1219061B (zh) 乳液制剂
WO2025030153A1 (en) Oral formulations of cannabinoids

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150216

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151125

R150 Certificate of patent or registration of utility model

Ref document number: 5847730

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250